SCHEMBL213582

SCHEMBL213582

CN(C(=O)NCc1cccc(F)c1F)[C@@H](CCCC(=O)O)COC(=O)Nc1nnc(-c2ccc(F)cc2)s1

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 8/20 0.42
CSNK2A1 P68400 8/20 0.42
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
RAB9A P51151 5/20 0.36
NPC1 O15118 3/20 0.36
KDM4E B2RXH2 5/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL211758 0.95 CSNK2A2 (0.41) CSNK2A2CSNK2A1RAB9ANPC1KDM4E
SCHEMBL210561 0.95 CSNK2A2 (0.41) CSNK2A2CSNK2A1HDAC1HDAC2RAB9A
SCHEMBL215001 0.94 CSNK2A2 (0.41) CSNK2A2CSNK2A1HDAC1HDAC2RAB9A
SCHEMBL212407 0.94 CSNK2A2 (0.41) CSNK2A2CSNK2A1HDAC1HDAC2RAB9A
SCHEMBL213027 0.94 RAB9A (0.45) CSNK2A2CSNK2A1HDAC1HDAC2RAB9A
SCHEMBL2723939 0.93 CSNK2A2 (0.39) CSNK2A2CSNK2A1HDAC1HDAC2RAB9A
SCHEMBL212087 0.92 CSNK2A2 (0.39) CSNK2A2CSNK2A1RAB9ANPC1KDM4E
SCHEMBL212508 0.92 KDM4E (0.42) CSNK2A2CSNK2A1RAB9ANPC1KDM4E
SCHEMBL2725740 0.90 CSNK2A2 (0.40) CSNK2A2CSNK2A1RAB9ANPC1KDM4E
SCHEMBL2724041 0.88 RXFP1 (0.40) CSNK2A2CSNK2A1HDAC1HDAC2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895582-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2014-11-25 US disclosed
US-8759374-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2014-06-24 US disclosed
US-20130053348-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS QIAN XIANGPING (US) 2013-02-28 US disclosed
US-20120135964-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS QIAN XIANGPING (US) 2012-05-31 US disclosed
US-8088793-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2012-01-03 US disclosed
EP-2195328-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Incorporated (US) 2010-06-16 EP disclosed
US-20090275537-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-11-05 US disclosed
WO-2009023193-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275537-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 CSNK2A2 534/4885CSNK2A1 714/4885HDAC1 1823/4885
US-20120135964-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS MYLK, MYH2, MYH10 CSNK2A2 534/4885CSNK2A1 714/4885HDAC1 1823/4885
US-20130053348-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS MYLK, MYH2, MYH10 CSNK2A2 534/4885CSNK2A1 714/4885HDAC1 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.